Jefferies initiated coverage of BillionToOne (BLLN) with a Hold rating and $117 price target The company is leveraging its Quantitative Counting Templates technology to create highly-sensitive assays, which should result in outsized growth, the analyst tells investors in a research note. The firm cites valuation for the Hold rating with the shares doubling since the initial public offering.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BLLN:
- BillionToOne, Inc.: Strong Market Position and Profitability Justify Buy Rating
- BillionToOne’s Innovative Platform Poised for Growth in Reproductive Health and Oncology Markets
- BillionToOne’s Innovative Sequencing Platform and Strong Growth Prospects Justify Buy Rating and $150 Price Target
- Balanced Outlook on BillionToOne, Inc.: High Growth Potential Amidst Competitive Challenges
- BillionToOne, Inc. Completes Successful IPO Raising $314 Million